Theravance Net Working Capital from 2010 to 2024

TBPH Stock  USD 8.34  0.21  2.46%   
Theravance Biopharma's Net Working Capital is decreasing with slightly volatile movements from year to year. Net Working Capital is estimated to finish at about 213.9 M this year. For the period between 2010 and 2024, Theravance Biopharma, Net Working Capital quarterly trend regression had mean deviation of  56,334,392 and range of 325.5 M. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
108.8 M
Current Value
213.9 M
Quarterly Volatility
75.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Theravance Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Theravance main balance sheet or income statement drivers, such as Depreciation And Amortization of 4 M, Interest Expense of 2.2 M or Total Revenue of 56.6 M, as well as many exotic indicators such as Price To Sales Ratio of 10.28, Dividend Yield of 0.0 or PTB Ratio of 3.06. Theravance financial statements analysis is a perfect complement when working with Theravance Biopharma Valuation or Volatility modules.
  
This module can also supplement Theravance Biopharma's financial leverage analysis and stock options assessment as well as various Theravance Biopharma Technical models . Check out the analysis of Theravance Biopharma Correlation against competitors.
For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.

Latest Theravance Biopharma's Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Theravance Biopharma over the last few years. It is Theravance Biopharma's Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Theravance Biopharma's overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Theravance Net Working Capital Regression Statistics

Arithmetic Mean286,608,606
Geometric Mean274,748,743
Coefficient Of Variation26.39
Mean Deviation56,334,392
Median316,197,000
Standard Deviation75,649,460
Sample Variance5722.8T
Range325.5M
R-Value(0.55)
Mean Square Error4281T
R-Squared0.31
Significance0.03
Slope(9,347,801)
Total Sum of Squares80119.8T

Theravance Net Working Capital History

2024213.9 M
2023108.8 M
2022324.7 M
2021191.3 M
2020269.8 M
2019226.8 M
2018434.3 M

About Theravance Biopharma Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Theravance Biopharma income statement, its balance sheet, and the statement of cash flows. Theravance Biopharma investors use historical funamental indicators, such as Theravance Biopharma's Net Working Capital, to determine how well the company is positioned to perform in the future. Although Theravance Biopharma investors may use each financial statement separately, they are all related. The changes in Theravance Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Theravance Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Theravance Biopharma Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Theravance Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital108.8 M213.9 M

Currently Active Assets on Macroaxis

When determining whether Theravance Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Theravance Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Theravance Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Theravance Biopharma Stock:
Check out the analysis of Theravance Biopharma Correlation against competitors.
For more detail on how to invest in Theravance Stock please use our How to Invest in Theravance Biopharma guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Complementary Tools for Theravance Stock analysis

When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Global Correlations
Find global opportunities by holding instruments from different markets
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Is Theravance Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Theravance Biopharma. If investors know Theravance will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Theravance Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.89)
Revenue Per Share
1.191
Quarterly Revenue Growth
0.392
Return On Assets
(0.06)
Return On Equity
(0.16)
The market value of Theravance Biopharma is measured differently than its book value, which is the value of Theravance that is recorded on the company's balance sheet. Investors also form their own opinion of Theravance Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Theravance Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Theravance Biopharma's market value can be influenced by many factors that don't directly affect Theravance Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Theravance Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Theravance Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Theravance Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.